BioArctic AB (publ) (BRCTF)
USD 15.67
(0.0%)
USD 15.67
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 275.38 Million SEK | 6735.23% |
| 2022 | 4.02 Million SEK | 103.18% |
| 2021 | -126.56 Million SEK | -69.91% |
| 2020 | -74.69 Million SEK | -160.38% |
| 2019 | 123.36 Million SEK | -74.98% |
| 2018 | 487.88 Million SEK | 2171.89% |
| 2017 | 26.01 Million SEK | -71.33% |
| 2016 | 64.23 Million SEK | 1093.21% |
| 2015 | 6.36 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -67.97 Million SEK | -18.47% |
| 2024 Q1 | -57.37 Million SEK | 23.31% |
| 2023 Q3 | 145.52 Million SEK | 251.11% |
| 2023 Q4 | -74.8 Million SEK | -151.41% |
| 2023 Q2 | -96.3 Million SEK | -131.02% |
| 2023 Q1 | 310.46 Million SEK | 674.1% |
| 2023 FY | - SEK | 6735.23% |
| 2022 Q3 | 140.75 Million SEK | 435.22% |
| 2022 FY | - SEK | 103.18% |
| 2022 Q4 | -54.07 Million SEK | -138.42% |
| 2022 Q2 | -41.98 Million SEK | -3.99% |
| 2022 Q1 | -40.37 Million SEK | -11.51% |
| 2021 FY | - SEK | -69.91% |
| 2021 Q2 | -30.55 Million SEK | -19.34% |
| 2021 Q3 | -34.05 Million SEK | -11.47% |
| 2021 Q4 | -36.21 Million SEK | -6.33% |
| 2021 Q1 | -25.6 Million SEK | 8.24% |
| 2020 Q1 | 7.41 Million SEK | 138.58% |
| 2020 Q4 | -27.89 Million SEK | -58.29% |
| 2020 Q3 | -17.62 Million SEK | 50.18% |
| 2020 Q2 | -35.37 Million SEK | -577.2% |
| 2020 FY | - SEK | -160.38% |
| 2019 Q4 | -19.21 Million SEK | -145.5% |
| 2019 Q2 | 130.36 Million SEK | 550.67% |
| 2019 Q1 | 20.03 Million SEK | -95.35% |
| 2019 FY | - SEK | -74.98% |
| 2019 Q3 | -7.82 Million SEK | -106.0% |
| 2018 Q2 | 7.18 Million SEK | -65.4% |
| 2018 FY | - SEK | 2171.89% |
| 2018 Q4 | 430.87 Million SEK | 1159.79% |
| 2018 Q3 | 34.2 Million SEK | 376.09% |
| 2018 Q1 | 20.76 Million SEK | 32.78% |
| 2017 Q1 | 1.46 Million SEK | -98.48% |
| 2017 FY | - SEK | -71.33% |
| 2017 Q2 | 3.46 Million SEK | 135.87% |
| 2017 Q4 | 15.63 Million SEK | 1288.72% |
| 2017 Q3 | 1.12 Million SEK | -67.5% |
| 2016 Q1 | -5.87 Million SEK | 0.0% |
| 2016 FY | - SEK | 1093.21% |
| 2016 Q4 | 96.39 Million SEK | 1063.5% |
| 2016 Q3 | -10 Million SEK | 8.03% |
| 2016 Q2 | -10.87 Million SEK | -85.08% |
| 2015 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 487.672% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 4744.817% |
| SQZ Biotechnologies Company | -64.14 Million USD | 529.346% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 1685.417% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | -192.846% |
| Mesoblast Limited | -62.38 Million USD | 541.398% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 18028.269% |
| Genus plc | 73.7 Million USD | -273.659% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 4265.262% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 7863.946% |
| Marizyme, Inc. | -34.28 Million USD | 903.312% |
| ContraFect Corporation | -64.99 Million USD | 523.679% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 3239.387% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 6184.294% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 19745.13% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 10513.78% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 11950.617% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 53258.793% |
| Accustem Sciences Inc. | -3.74 Million USD | 7450.673% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 671.022% |
| EV Biologics, Inc. | -1.26 Million USD | 21833.095% |
| Q BioMed Inc. | -617.62 Thousand USD | 44687.843% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -7609.602% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 43645.918% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 12154.643% |
| Biomind Labs Inc. | -1.03 Million USD | 26719.039% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | -2688.164% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 3945.502% |
| Skye Bioscience, Inc. | -13.54 Million USD | 2132.744% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 18614.507% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 1101648.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 7189.709% |
| IMV Inc. | -35.52 Million USD | 875.227% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 1835.297% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 11106.842% |
| GB Sciences, Inc. | -1.41 Million USD | 19495.021% |
| Alpha Cognition Inc. | -9.7 Million USD | 2937.403% |
| HST Global, Inc. | -5303.00 USD | 5193141.675% |
| CSL Limited | 4.78 Billion USD | 94.25% |
| Halberd Corporation | -74.27 Thousand USD | 370846.779% |
| Enzolytics Inc. | -2.12 Million USD | 13077.532% |
| Resverlogix Corp. | -11.74 Million USD | 2445.316% |
| Affymax, Inc. | -14.29 Million USD | 2026.457% |
| SYBLEU INC | -141.57 Thousand USD | 194622.183% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 9090.714% |
| argenx SE | -216.02 Million USD | 227.48% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 597.636% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -22528.348% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 18472.533% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -72591.398% |
| AVAX Technologies, Inc. | -6.11 Million USD | 4605.203% |
| Zenith Capital Corp. | -8.6 Million USD | 3299.942% |
| Genscript Biotech Corporation | -248.71 Million USD | 210.722% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 1580876.075% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 11356.546% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 156548.233% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 794.775% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 9621.299% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 26419.778% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -4095482.986% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 15836.409% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 14436.271% |
| BioStem Technologies, Inc. | -7.55 Million USD | 3745.75% |
| ONE Bio Corp. | 13.61 Million USD | -1922.964% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 152173.577% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 13487.798% |
| Agentix Corp. | -1.37 Million USD | 20175.509% |
| LadRx Corporation | 412.28 Thousand USD | -66695.623% |
| Cell Source, Inc. | -4.27 Million USD | 6545.531% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 75092.171% |
| Regen BioPharma, Inc. | 1.46 Million USD | -18685.489% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 29491.888% |
| NovAccess Global Inc. | -1.03 Million USD | 26712.659% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -3010.382% |
| Itoco Inc. | -1.86 Million USD | 14834.496% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 72642.806% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 24776.254% |
| Kadimastem Ltd | -2.62 Million USD | 10593.408% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 115252.415% |
| CytoDyn Inc. | -18.02 Million USD | 1627.467% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 348563.222% |
| Mobile Lads Corp. | -2.24 Million USD | 12387.705% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 2252017.573% |
| Qrons Inc. | -40.08 Thousand USD | 687176.171% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 56801.559% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -52112.698% |
| Rebus Holdings, Inc. | -951 Thousand USD | 29057.624% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 26030.735% |
| International Stem Cell Corporation | 202 Thousand USD | -136230.198% |
| Bioxytran, Inc. | -3.82 Million USD | 7308.806% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 523251.596% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 11285.809% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 867.758% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 612071.111% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 10157.962% |
| Neutra Corp. | -181.24 Thousand USD | 152040.17% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 1466.075% |
| PureTech Health plc | -11.62 Million USD | 2468.513% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 1466.168% |
| IXICO plc | -707 Thousand USD | 39051.485% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 3683.435% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 669.617% |
| CSL Limited | 4.73 Billion USD | 94.182% |
| Cellectis S.A. | -92.63 Million USD | 397.279% |